User:Mr. Ibrahem/Lemborexant

Mr. Ibrahem/Lemborexant
Clinical data
Trade names	Dayvigo
Other names	E-2006
AHFS/Drugs.com	Monograph
License data	US DailyMed: Lemborexant;
Pregnancy; category	AU: B3; ;
Routes of; administration	By mouth
Drug class	Orexin antagonist
Legal status
Legal status	AU: S4 (Prescription only); US: Schedule IV;
Pharmacokinetic data
Protein binding	94%
Metabolism	Liver (major: CYP3A4, minor: CYP3A5)
Metabolites	M10
Elimination half-life	17–19 hours
Excretion	Feces: 57.4%; Urine: 29.1%
Identifiers
	IUPAC name (1R,2S)-2-[(2,4-Dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide;
Chemical and physical data
Formula	C22H20F2N4O2
Molar mass	410.425 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=NC(=NC=C1OCC2(CC2C(=O)NC3=NC=C(C=C3)F)C4=CC(=CC=C4)F)C;
	InChI InChI=1S/C22H20F2N4O2/c1-13-19(11-25-14(2)27-13)30-12-22(15-4-3-5-16(23)8-15)9-18(22)21(29)28-20-7-6-17(24)10-26-20/h3-8,10-11,18H,9,12H2,1-2H3,(H,26,28,29)/t18-,22+/m0/s1; Key:MUGXRYIUWFITCP-PGRDOPGGSA-N;

Lemborexant, sold under the brand name Dayvigo, is a medication used to treat trouble sleeping.^[2] It may be used for trouble falling asleep or staying asleep.^[2] It is taken by mouth.

Common side effects include sleepiness.^[2] Other side effect may include poor coordination, sleep paralysis, sleep walking, misuse, and suicide.^[2]^[3] Safety in pregnancy is unclear.^[4] It is an orexin receptor blocker.^[2]

Lemborexant was approved for medical use in the United States in 2019.^[2] In the United States it costs about 320 USD per month as of 2021.^[5] In the United States it is a Schedule IV controlled substance.^[3]

References[edit]

^ ^a ^b "Dayvigo". Therapeutic Goods Administration (TGA). 23 July 2021. Archived from the original on 5 September 2021. Retrieved 5 September 2021.
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ ^o ^p "Dayvigo- lemborexant tablet, film coated". DailyMed. Archived from the original on 24 June 2021. Retrieved 17 June 2021.
^ ^a ^b ^c "Lemborexant Monograph for Professionals". Drugs.com. Archived from the original on 24 September 2020. Retrieved 21 November 2021.
^ "Lemborexant (Dayvigo) Use During Pregnancy". Drugs.com. Archived from the original on 27 August 2021. Retrieved 21 November 2021.
^ "Dayvigo Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 21 November 2021.

[Dayvigo_APM_summary-1] "Dayvigo". Therapeutic Goods Administration (TGA). 23 July 2021. Archived from the original on 5 September 2021. Retrieved 5 September 2021.

[PI2021-2] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ ^o ^p "Dayvigo- lemborexant tablet, film coated". DailyMed. Archived from the original on 24 June 2021. Retrieved 17 June 2021.

[AHFS2021-3] "Lemborexant Monograph for Professionals". Drugs.com. Archived from the original on 24 September 2020. Retrieved 21 November 2021.

[4] "Lemborexant (Dayvigo) Use During Pregnancy". Drugs.com. Archived from the original on 27 August 2021. Retrieved 21 November 2021.

[5] "Dayvigo Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 21 November 2021.

[1]

[2]

[3]

[4]

[5]